Brazil · Delayed Price · Currency is BRL Vittia Earnings Call Transcripts
Fiscal Year 2026
-
Despite a tough agribusiness market, revenue and cash flow improved, but margins compressed due to mix and competition. Operational discipline, innovation, and shareholder returns were prioritized, with only modest growth and margin stabilization expected for 2026.
-
Revenue and EBITDA declined amid challenging agribusiness conditions, but net debt was reduced by 20% and cash flow improved. Management remains optimistic, focusing on innovation, cost control, and international expansion, with expectations for margin recovery and growth in biological solutions.
Fiscal Year 2025
-
Q3 2025 saw 12% revenue growth and strong cash flow despite sector challenges, with innovation in biologicals and expansion in Mexico. Margins improved in micro soil, while foliar demand lagged. Conservative financial management and ongoing share buybacks support stability.
-
Revenue and cash flow grew despite margin pressure from a shift to lower-value products, with strong performance in soil fertilizers and continued investment in innovation. Leverage improved, shareholder returns increased, and new product launches exceeded expectations.
-
Net revenue rose 13.4% year-over-year in Q1 2025, led by strong soil fertilizer sales but offset by lower margins and a negative net result. Cost rationalization and innovation, including the Triunfe launch, position the company for improved performance as market conditions stabilize.
Fiscal Year 2024
-
Gross and net revenues grew in 2024, with strong Q4 performance in biologicals, but full-year net income and EBITDA declined due to margin pressures and higher fiscal charges. The company expects a healthier 2025, leveraging its robust balance sheet and new product launches, despite ongoing credit and market challenges.
-
Net revenue grew 6.2% in Q3 2024, but net income and EBITDA declined due to drought, price pressure, and increased competition in biologicals. The company maintained strong cost control, invested in innovation, and executed share buybacks, with a positive outlook for Q4 and off-season crops.
-
Adjusted gross revenue and net revenue grew significantly year-over-year in Q2 2024, driven by strong performance in biologicals and all product lines, despite ongoing price pressures and negative net income. CapEx and net debt were reduced, and the company advanced R&D and share buybacks.